59
MUVON Therapeutics Appoints Christine Günther, MD, PhD, as CTO
Zurich, Switzerland – December 18, 2025 – MUVON Therapeutics, a clinical-stage biotechnology company developing regenerative therapies for skeletal muscle, announced the appointment of Christine Günther, MD, PhD, as Chief Technology Officer (CTO), effective December 1, 2025.
Key Highlights:
- Extensive Experience: Dr. Günther brings over 30 years of experience in translating regenerative medicine innovations to clinical application, with a strong background in cell and gene therapy.
- Leadership & Entrepreneurship: She has a proven track record of scaling cell therapy businesses, previously serving as CEO and Medical Director of apceth (now Minaris Regenerative Medicine) for over 12 years.
- Expertise: Her expertise encompasses iPSC technology, CMC, GMP manufacturing, regulatory affairs, and clinical translation – crucial for advancing MUVON’s personalized tissue-engineered muscle regeneration treatments.
- Positive Phase 2 Results: Dr. Günther joins MUVON following the announcement of promising Phase 2 results for its muscle precursor cell-based therapy in restoring bladder health (SUISSE-MPC2 study).
- SUISSE-MPC2 Study Details: The Phase 2 SUISSE-MPC2 trial (NCT05534269) demonstrated statistically significant improvements in stress incontinence episode frequency and 24-hour pad weight in women with stress urinary incontinence (SUI) who had failed prior treatments. The therapy utilizes a patient’s own muscle precursor cells (MPCCOL) delivered via a proprietary ultrasound-guided device.
Quotes:
- Dr. Deana Mohr, CEO of MUVON Therapeutics: “Her broad-based experience, energy, and leadership…will help propel us through the next stage of our journey.”
- Dr. Christine Günther, CTO of MUVON Therapeutics: “The company’s innovative approach to regenerative medicine has tremendous potential…I look forward to working with the team to accelerate development and bring transformative treatments to patients.”
Contact:
Dr. Deana Mohr, CEO
[email protected]
